TDACU Closes $100M IPO

TL;DR

TDACU just raised $100M via IPO, units trading at $10.

AI Summary

Translational Development Acquisition Corp. (TDACU) announced on December 20, 2024, the closing of its initial public offering of 10,000,000 units at $10.00 per unit. Each unit consists of one share of Class A ordinary shares and one-half of a redeemable warrant. The gross proceeds from the offering were $100,000,000.

Why It Matters

This IPO provides Translational Development Acquisition Corp. with significant capital, enabling potential future acquisitions or business development activities.

Risk Assessment

Risk Level: medium — The company is a SPAC (Special Purpose Acquisition Company) which inherently carries higher risk due to its reliance on future acquisitions.

Key Numbers

• $100.0M — IPO Gross Proceeds (Capital raised from the initial public offering.)
• 10.0M — Units Offered (Number of units sold in the IPO.)
• $10.00 — Price Per Unit (The offering price for each unit.)

Key Players & Entities

• Translational Development Acquisition Corp. (company) — Filer
• TDACU (company) — Ticker Symbol
• 10,000,000 units (dollar_amount) — Number of units in IPO
• $10.00 per unit (dollar_amount) — Price per unit in IPO
• $100,000,000 (dollar_amount) — Gross proceeds from IPO
• December 20, 2024 (date) — Date of IPO closing

FAQ

Key Financial Figures

• $0.0001 — nsisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemab
• $11.50 — ordinary share at an exercise price of $11.50 TDACW The Nasdaq Stock Market LLC
• $10.00 — ents. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to
• $172,500,000 — rating gross proceeds to the Company of $172,500,000. Each Unit consists of one Class A ordi
• $1.00 — hare at $11.50 per share, at a price of $1.00 per warrant, or $7,075,000 in the aggre
• $7,075,000 — re, at a price of $1.00 per warrant, or $7,075,000 in the aggregate. Of those 7,075,000 Pr
• $174,225,000 — . Item 8.01 Other Events. A total of $174,225,000 net proceeds from the IPO and the sale

Filing Documents

• tm2422367d22_8k.htm (8-K) — 54KB
• tm2422367d22_ex1-1.htm (EX-1.1) — 249KB
• tm2422367d22_ex3-1.htm (EX-3.1) — 297KB
• tm2422367d22_ex4-1.htm (EX-4.1) — 95KB
• tm2422367d22_ex10-1.htm (EX-10.1) — 83KB
• tm2422367d22_ex10-2.htm (EX-10.2) — 101KB
• tm2422367d22_ex10-3.htm (EX-10.3) — 49KB
• tm2422367d22_ex10-4.htm (EX-10.4) — 45KB
• tm2422367d22_ex10-5.htm (EX-10.5) — 47KB
• tm2422367d22_ex10-6.htm (EX-10.6) — 10KB
• tm2422367d22_ex10-7.htm (EX-10.7) — 99KB
• tm2422367d22_ex99-1.htm (EX-99.1) — 7KB
• tm2422367d22_ex99-2.htm (EX-99.2) — 7KB
• 0001104659-24-132134.txt ( ) — 1634KB
• tdacu-20241220.xsd (EX-101.SCH) — 4KB
• tdacu-20241220_def.xml (EX-101.DEF) — 27KB
• tdacu-20241220_lab.xml (EX-101.LAB) — 37KB
• tdacu-20241220_pre.xml (EX-101.PRE) — 26KB
• tm2422367d22_8k_htm.xml (XML) — 8KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On December 24, 2024, Translational Development Acquisition Corp. (the " Company ") consummated its initial public offering (" IPO "), which consisted of 17,250,000 units(the " Units "), including the exercise in full by BTIG, LLC, as underwriter (the " Underwriter "), of an option to purchase up to 2,250,000 Units at the offering price to cover over-allotments. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $172,500,000. Each Unit consists of one Class A ordinary share, $0.0001 par value per share (the " Class A Ordinary Shares "), of the Company, and one-half of one redeemable warrant (each a " Warrant "), each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share. In connection with the IPO, the Company entered into the following agreements, forms of which were previously filed as exhibits to the Company's registration An Underwriting Agreement, dated December 23, 2024, between the Company and Underwriter, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference. A Warrant Agreement, dated December 23, 2024, between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the " Warrant Agreement "), a copy of which is attached as Exhibit 4.1 hereto and incorporated herein by reference. An Investment Management Trust Agreement, dated December 23, 2024, between the Company and Continental Stock Transfer & Trust Company, as trustee, a copy of which is attached as Exhibit 10.1 hereto and incorporated herein by reference. A Registration Rights Agreement, dated December 23, 2024, among the Company and certain security holders, a copy of which is attached as Exhibit 10.2 hereto and incorporated herein by reference. A Private Placement Warrants Purchase Agreement, dated December 23, 202

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. Simultaneously with the closing of the IPO, pursuant to the Private Placement Warrants Purchase Agreements, the Company completed the private placement of an aggregate of 7,075,000 warrants (the "Private Placement Warrants") to the Sponsor and the Underwriter, each exercisable to purchase one Class A Ordinary Share at $11.50 per share, at a price of $1.00 per warrant, or $7,075,000 in the aggregate. Of those 7,075,000 Private Placement Warrants, the Sponsor purchased 4,825,000 Private Placement Warrants and the Underwriter purchased 2,250,000 Private Placement Warrants. The Private Placement Warrants (and underlying securities) are identical to the Warrants included in the Units sold in the IPO, except as otherwise disclosed in the Registration Statement. No underwriting discounts or commissions were paid with respect to such sale. The issuance of the Private Placement Warrants was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended.

02 Departure of Directors or Certain

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 20, 2024, in connection with the IPO, E. Premkumar Reddy, Curtis T. Keith, Matthew A. Kestenbaum, and Christopher Jarratt (the " New Directors " and, collectively with Michael B. Hoffman, the " Directors ") were appointed to the board of directors of the Company (the " Board "). Effective December 20, 2024, Matthew A. Kestenbaum and Christopher Jarratt were appointed to the Board's Audit Committee, Christopher Jarratt and Curtis E. Keith were appointed to the Board's Compensation Committee, and E. Premkumar Reddy and Matthew A. Kestenbaum were appointed to the Board's Nominating and Corporate Governance Committee. On December 23, 2024, the Company entered into indemnity agreements with each of the Directors, and Avanindra C. Das, its chief financial officer, that require the Company to indemnify each of them to the fullest extent permitted by applicable law and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. The foregoing summary of the indemnity agreements does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the form of indemnity agreement, which is filed as Exhibit 10.7 to this Current Report on Form 8-K and incorporated in this Item 5.02 by reference.

03 Amendments to Articles of Incorporation

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On December 20, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the " Amended and Restated Memorandum and Articles of Association ") with the Cayman Islands Registrar of Companies, which was effective on December 20, 2024. The terms of the Amended and Restated Memorandum and Articles of Association are set forth in the Registration Statement and are incorporated herein by reference. A copy of the Amended and Restated Memorandum and Articles of Association is attached as Exhibit 3.1 hereto and incorporated herein by reference.

01 Other Events

Item 8.01 Other Events. A total of $174,225,000 net proceeds from the IPO and the sale of the Private Placement Warrants, was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee. Except with respect to interest earned on the funds in the trust account that may be released to the Company to pay its income taxes and for winding up and dissolution expenses, the funds held in the trust account will not be released from the trust account until the earliest of (i) the completion of the Company's initial business combination, (ii) the redemption of the Company's public shares if it is unable to complete its initial business combination within 18 months from the closing of the IPO (as such date may be extended by shareholder approval to amend the Amended and Restated Memorandum and Articles of Association to extend the date by which we must consummate our initial business combination, or by such earlier liquidation date as the Board may approve), subject to applicable law, and (iii) the redemption of the Company's public shares properly submitted in connection with a shareholder vote to amend the Amended and Restated Memorandum and Articles of Association to modify the substance or timing of its obligation to redeem 100% of the Company's public shares if it has not consummated an initial business combination within 18 months from the closing of the IPO or with respect to any other material provisions relating to shareholders' rights or pre-initial business combination activity. On December 23, 2024, the Company issued a press release announcing the pricing of the IPO, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K. On December 24, 2024, the Company issued a press release announcing the closing of the IPO, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being filed herewith: 1.1 Underwriting Agreement, dated December 23, 2024, by and between the Company and the Underwriter. 3.1 Amended and Restated Memorandum and Articles of Association of the Company. 4.1 Warrant Agreement, dated December 23, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent. 10.1 Investment Management Trust Account Agreement, dated December 23, 2024, by and between the Company and Continental Stock Transfer & Trust Company, as trustee. 10.2 Registration Rights Agreement, dated December 23, 2024, by and among the Company and certain security holders. 10.3 Private Placement Warrants Purchase Agreement, dated December 23, 2024, by and between the Company and the Sponsor. 10.4 Private Placement Warrants Purchase Agreement, dated December 23, 2024, by and between the Company and the Underwriter. 10.5 Letter Agreement, dated December 23, 2024, by and among the Company, its officers and directors and the Sponsor. 10.6 Administrative Services Agreement, dated December 23, 2024, by and between the Company and the Sponsor 10.7 Form of Indemnity Agreement. 99.1 Press Release, dated December 23, 2024. 99.2 Press Release, dated December 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 27, 2024 TRANSLATIONAL DEVELOPMENT ACQUISITION CORP. By: /s/ Michael B. Hoffman Name: Michael B. Hoffman Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR